Neutral antagonism at the cannabinoid 1 receptor: A safer treatment for obesity

Molecular Psychiatry

Volumn 18, Issue 12, 2013, Pages 1294-1301

  Meye, F J ^a   Trezza, V ^a,b   Vanderschuren, L J M J ^a,c   Ramakers, G M J ^a   Adan, R A H ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b ROMA TRE UNIVERSITY   (Italy)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

cannabinoid 1 receptor; constitutive activity; inverse agonist; mesolimbic dopamine system; obesity

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; NESS 0327; O 2050; RIMONABANT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY; ARTICLE; BASOLATERAL AMYGDALA; CONTROLLED STUDY; DEPRESSION; DRUG ANTAGONISM; DRUG EFFICACY; DRUG SAFETY; FOOD INTAKE; GABAERGIC TRANSMISSION; GLUTAMATERGIC NEUROTRANSMISSION; MALE; MOTIVATION; MOUSE; NEUROTRANSMISSION; NONHUMAN; OBESITY; PRIORITY JOURNAL; RAT; REWARD; VENTRAL TEGMENTUM; WEIGHT REDUCTION;

AMYGDALA; ANIMALS; ANXIETY; DOPAMINERGIC NEURONS; EATING; GABAERGIC NEURONS; HUMANS; MALE; MICE; MICE, INBRED C57BL; OBESITY; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; VENTRAL TEGMENTAL AREA; WEIGHT GAIN;

EID: 84888290970     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2012.145     Document Type: Article

References (51)

1. Hotamisligil GS. Inflammation and metabolic disorders. Nature 2006; 444: 860-867.
2. World-Health-Organization. Obesity: Preventing and managing the global epidemic. Report of a WHO consultation. World Health Organ Tech Rep Ser 2000; 894: I-xii, 1-253.
3. Berthoud HR, Lenard NR, Shin AC. Food reward, hyperphagia, and obesity. Am J Physiol Regul Integr Comp Physiol 2011; 300: R1266-R1277.
4. Adan RAH, Vanderschuren LJMJ, La Fleur SE. Anti-obesity drugs and neural circuits of feeding. Trends Pharmacol Sci 2008; 29: 208-217.
5. Halford JC, Boyland EJ, Blundell JE, Kirkham TC, Harrold JA. Pharmacological management of appetite expression in obesity. Nat Rev Endocrinol 2010; 6: 255-269.
6. Wadden TA, Butryn ML, Wilson C. Lifestyle modification for the management of obesity. Gastroenterology 2007; 132: 2226-2238.
7. Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoidoriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009; 205: 171-174.
8. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001; 410: 822-825.
9. Di Marzo V, Ligresti A, Cristino L. The endocannabinoid system as a link between homoeostatic and hedonic pathways involved in energy balance regulation. Int J Obes (Lond) 2009; 33(Suppl 2): S18-S24.
10. Di Marzo V, Matias I. Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005; 8: 585-589.
11. Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A. Efficacy and safety of the weight-loss drug rimonabant: A meta-Analysis of randomised trials. Lancet 2007; 370: 1706-1713.
12. Lazary J, Juhasz G, Hunyady L, Bagdy G. Personalized medicine can pave the way for the safe use of CB1 receptor antagonists. Trends Pharmacol Sci 2011; 32: 270-280.
13. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: The STRADIVARIUS randomized controlled trial. JAMA 2008; 299: 1547-1560.
14. Pan X, Ikeda SR, Lewis DL. SR 141716A acts as an inverse agonist to increase neuronal voltage-dependent Ca2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol Pharmacol 1998; 54: 1064-1072.
15. Canals M, Milligan G. Constitutive activity of the cannabinoid CB1 receptor regulates the function of co-expressed Mu opioid receptors. J Biol Chem 2008; 283: 11424-11434.
16. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005; 76: 1307-1324.
17. Sink KS, McLaughlin PJ, Wood JAT, Brown C, Fan P, Vemuri VK et al. The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology 2008; 33: 946-955.
18. Salamone JD, McLaughlin PJ, Sink K, Makriyannis A, Parker LA. Cannabinoid CB1 receptor inverse agonists and neutral antagonists: Effects on food intake, food-reinforced behavior and food aversions. Physiol Behav 2007; 91: 383-388.
19. Sink KS, Segovia KN, Sink J, Randall PA, Collins LE, Correa M et al. Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonsits in rats: Comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol 2010; 20: 112-122.
20. Ruiu S, Pinna GA, Marchese G, Mussinu JM, Saba P, Tambaro S et al. Synthesis and characterization of NESS 0327: A novel putative antagonist of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 2003; 306: 363-370.
21. Tambaro S, Mongeau R, Dessi C, Pani L, Ruiu S. Modulation of ATP-mediated contractions of the rat vas deferens through presynaptic cannabinoid receptors. Eur J Pharmacol 2005; 525: 150-153.
22. Dunlop BW, Nemeroff CB. The role of dopamine in the pathophysiology of depression. Arch Gen Psychiatry 2007; 64: 327-337.
23. Nestler EJ, Carlezon Jr. WA. The mesolimbic dopamine reward circuit in depression. Biol Psychiatry 2006; 59: 1151-1159.
24. Zweifel LS, Fadok JP, Argilli E, Garelick MG, Jones GL, Dickerson TM et al. Activation of dopamine neurons is critical for aversive conditioning and prevention of generalized anxiety. Nat Neurosci 2011; 14: 620-626.
25. Tye KM, Prakash R, Kim SY, Fenno LE, Grosenick L, Zarabi H et al. Amygdala circuitry mediating reversible and bidirectional control of anxiety. Nature 2011; 471: 358-362.
26. Wallace TL, Stellitano KE, Neve RL, Duman RS. Effects of cyclic adenosine monophosphate response element binding protein overexpression in the basolateral amygdala on behavioral models of depression and anxiety. Biol Psychiatry 2004; 56: 151-160.
27. de Rover M, Meye FJ, Ramakers GM. Presynaptic metabotropic glutamate receptors regulate glutamatergic input to dopamine neurons in the ventral tegmental area. Neuroscience 2008; 154: 1318-1323.
28. Mathon DS, Lesscher HM, Gerrits MA, Kamal A, Pintar JE, Schuller AG et al. Increased gabaergic input to ventral tegmental area dopaminergic neurons associated with decreased cocaine reinforcement in mu-opioid receptor knockout mice. Neuroscience 2005; 130: 359-367.
29. Trezza V, Baarendse PJ, Vanderschuren LJ. Prosocial effects of nicotine and ethanol in adolescent rats through partially dissociable neurobehavioral mechanisms. Neuropsychopharmacology 2009; 34: 2560-2573.
30. Brussaard AB, Kits KS, de Vlieger TA. Postsynaptic mechanism of depression of GABAergic synapses by oxytocin in the supraoptic nucleus of immature rat. J Physiol 1996; 497(Pt 2): 495-507.
31. Ikemoto S, Wise RA. Mapping of chemical trigger zones for reward. Neuropharmacology 2004; 47(Suppl 1): 190-201.
32. McBride WJ, Murphy JM, Ikemoto S. Localization of brain reinforcement mechanisms: Intracranial self-Administration and intracranial place-conditioning studies. Behav Brain Res 1999; 101: 129-152.
33. Fields HL, Hjelmstad GO, Margolis EB, Nicola SM. Ventral tegmental area neurons in learned appetitive behavior and positive reinforcement. Annu Rev Neurosci 2007; 30: 289-316.
34. Treadway MT, Zald DH. Reconsidering anhedonia in depression: Lessons from translational neuroscience. Neurosci Biobehav Rev 2011; 35: 537-555.
35. Matyas F, Urban GM, Watanabe M, Mackie K, Zimmer A, Freund TF et al. Identification of the sites of 2-Arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area. Neuropharmacology 2008; 54: 95-107.
36. Szabo B, Siemes S, Wallmichrath I. Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur J Neurosci 2002; 15: 2057-2061.
37. Hájos N, Freund TF. Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology 2002; 43: 503-510.
38. Lan R, Liu Q, Fan P, Lin S, Fernando SR, MacCallion D et al. Structure-Activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem 1999; 42: 769-776.
39. Kathuria S, Gaetani S, Fegley D, Valino F, Duranti A, Tontini A et al. Modulation of anxiety through blockade of anandamide hydrolysis. Nat Med 2003; 9: 76-81.
40. Makara JK, Mor M, Fegley D, Szabo SI, Kathuria S, Astarita G et al. Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus. Nat Neurosci 2005; 8: 1139-1141.
41. Walker DL, Davis M. The role of amygdala glutamate receptors in fear learning, fear-potentiated startle, and extinction. Pharmacol Biochem Behav 2002; 71: 379-392.
42. Domenici MR, Azad SC, Marsicano G, Schierloh A, Wotjak CT, Dodt HU et al. Cannabinoid receptor type 1 located on presynaptic terminals of principal neurons in the forebrain controls glutamatergic synaptic transmission. J Neurosci 2006; 26: 5794-5799.
43. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: Stimulation of eating by 2-Arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550-557.
44. Rumsfeld JS, Nallamothu BK. The hope and fear of rimonabant. JAMAA 2008; 299: 1601-1602.
45. Murray EA, Wise SP, Drevets WC. Localization of dysfunction in major depressive disorder: Prefrontal cortex and amygdala. Biol Psychiatry 2011; 69: E43-e54.
46. Marsicano G, Wotjak CT, Azad SC, Bisogno T, Rammes G, Cascio MG et al. The endogenous cannabinoid system controls extinction of aversive memories. Nature 2002; 418: 530-534.
47. Orio L, Edwards S, George O, Parsons LH, Koob GF. A role for the endocannabinoid system in the increased motivation for cocaine in extended-Access conditions. J Neurosci 2009; 29: 4846-4857.
48. McGlinchey JB, Zimmerman M, Young D, Chelminski I. Diagnosing major depressive disorder VIII: Are some symptoms better than others? J Nerv Ment Dis 2006; 194: 785-790.
49. McLaughlin PJ, Winston K, Swezey L, Wisniecki A, Aberman J, Tardif DJ et al. The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and the food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol 2007; 14: 583-588.
50. Hentges ST, Low MJ, Williams JT. Differential regulation of synaptic inputs by constitutively released endocannabinoids and exogenous cannabinoids. J Neurosci 2005; 25: 9746-9751.
51. Sinnayah P, Jobst EE, Rathner JA, Caldera-Siu AD, Tonelli-Lemos L, Eusterbrock AJ et al. Feeding induced by cannabinoids is mediated independently of the melanocortin system. PLoS One 2008; 3: E2202.